Literature DB >> 15528451

P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice.

Seonghee Park1, Patrick J Sinko.   

Abstract

Efflux transporters such as P-glycoprotein (P-gp) and multidrug resistance-associated proteins (Mrps) and their contributions to saquinavir (SQV) brain uptake were characterized. Cerebral flow rate was estimated from diazepam uptake and brain vascular volume was assessed using inulin. Mice brains were perfused with buffer containing SQV alone or coperfused with different concentrations of GF120918, a P-gp inhibitor or MK571, a specific Mrp family inhibitor. Inulin, a nonabsorbable marker, was also coperfused in all studies to assess whether the inhibitors altered the physical integrity of the blood-brain barrier (BBB). The estimated cerebral flow rate using diazepam was 250 ml.100g(-1.)min(-1). The brain vascular volume, estimated using inulin, was almost constant (0.94 +/- 0.03 ml.100 g(-1), n = 12) during the perfusion study. SQV uptake kinetics was linear during the sampling period. Inclusion of 10 muM GF120918 in the perfusate resulted in a more than 7-fold increase in the brain distributional volume (i.e., uptake) of SQV. Inclusion of 100 muM MK571 in the perfusate increased SQV apparent brain uptake by more than 4.4-fold, suggesting, for the first time, that Mrp transporters may play an important role in the brain uptake and retention of SQV. Neither GF120918 nor MK571 altered the integrity of the BBB during the time course of the study. Although the current results reaffirm that SQV is a P-gp substrate, this is the first report implicating the Mrp transporter family in the limited brain uptake and retention of SQV in vivo in mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528451     DOI: 10.1124/jpet.104.076216

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  27 in total

1.  Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers.

Authors:  Hilda A Namanja; Dana Emmert; David A Davis; Christopher Campos; David S Miller; Christine A Hrycyna; Jean Chmielewski
Journal:  J Am Chem Soc       Date:  2011-09-09       Impact factor: 15.419

Review 2.  Placental ABC Transporters: Biological Impact and Pharmaceutical Significance.

Authors:  Anand A Joshi; Soniya S Vaidya; Marie V St-Pierre; Andrei M Mikheev; Kelly E Desino; Abner N Nyandege; Kenneth L Audus; Jashvant D Unadkat; Phillip M Gerk
Journal:  Pharm Res       Date:  2016-09-19       Impact factor: 4.200

3.  Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.

Authors:  Omar Janneh; Patrick G Bray; Elizabeth Jones; Christoph Wyen; Peter Chiba; David J Back; Saye H Khoo
Journal:  J Antimicrob Chemother       Date:  2010-03-17       Impact factor: 5.790

Review 4.  Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling.

Authors:  Elizabeth C M de Lange; Paulien G M Ravenstijn; Dorien Groenendaal; Tamara J van Steeg
Journal:  AAPS J       Date:  2005-10-07       Impact factor: 4.009

Review 5.  Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.

Authors:  Latoya Griffin; Pieter Annaert; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2011-06-22       Impact factor: 3.534

6.  Population PKPD modeling of BACE1 inhibitor-induced reduction in Aβ levels in vivo and correlation to in vitro potency in primary cortical neurons from mouse and guinea pig.

Authors:  Juliette Janson; Susanna Eketjäll; Karin Tunblad; Fredrik Jeppsson; Stefan Von Berg; Camilla Niva; Ann-Cathrin Radesäter; Johanna Fälting; Sandra A G Visser
Journal:  Pharm Res       Date:  2013-10-03       Impact factor: 4.200

7.  MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells.

Authors:  Mark Eilers; Upal Roy; Debasis Mondal
Journal:  Exp Biol Med (Maywood)       Date:  2008-06-05

Review 8.  Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS.

Authors:  Madhavan Nair; Rahul Dev Jayant; Ajeet Kaushik; Vidya Sagar
Journal:  Adv Drug Deliv Rev       Date:  2016-03-02       Impact factor: 15.470

9.  Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors.

Authors:  Naveed Shaik; Guoyu Pan; William F Elmquist
Journal:  J Pharm Sci       Date:  2008-12       Impact factor: 3.534

10.  Design and evaluation of a CXCR4 targeting peptide 4DV3 as an HIV entry inhibitor and a ligand for targeted drug delivery.

Authors:  In Heon Lee; Matthew S Palombo; Xiaoping Zhang; Zoltan Szekely; Patrick J Sinko
Journal:  Eur J Pharm Biopharm       Date:  2018-06-09       Impact factor: 5.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.